Wickland, D. P., McNinch, C., Jessen, E., Necela, B., Shreeder, B., Lin, Y., Knutson, K. L., Asmann, Y. W.

Background
Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint inhibitors. We previously developed a computa…